title: Gene-based therapies of neuromuscular disorders: an update and the pivotal role of patient organizations in their discovery and implementation.
abstract: This review updates the state-of-the art accomplishments of the multifaceted gene-based therapies, which include DNA or RNA as either therapeutic tools or targets for the treatment of neuromuscular diseases. It also provides insights into the key role that patient organizations have played in research and development; in particular, by addressing bottlenecks and generating boundary conditions that have contributed to scientific breakthroughs, and the effectiveness of innovation processes. Several gene therapy methods have reached the clinical stage and are now addressing both specific and classical issues related to this novel technology. Not ready yet for clinical application, genome editing is at its infancy. More rapidly progressing, RNA-based therapeutics, and especially exon skipping, exon inclusion and stop codon readthrough strategies, are about to move to the market. Most importantly, patients were at the forefront of this discovery process, from basic knowledge to innovation and translational research in a rapidly growing field of unmet medical needs. In recent years, Duchenne muscular dystrophy was the fertile ground for new therapeutic concepts that have been extended to other neuromuscular disorders, such as spinal muscular atrophy, myotonic dystrophies or fascioscapulohumeral dystrophy. In line with their longstanding policy, patient organizations will keep working in a proactive manner to bring together all stakeholders with a view to working out truly therapeutic solutions over a long-term perspective.
authors.affiliation: AFM-Telethon, Evry, Cedex, France.
authors.forename: Serge
authors.initials: S
authors.lastname: Braun
mesh_terms: D000818:Animals; D004247:DNA / Q000235:genetics / Q000627:therapeutic use; D015316:Genetic Therapy / Q000639:trends; D006801:Humans; D009468:Neuromuscular Diseases / Q000235:genetics* / Q000628:therapy*; D012313:RNA / Q000235:genetics / Q000627:therapeutic use
chemical_list: D012313:RNA; D004247:DNA
keywords: R&D; advocacy group; gene-based; motoneuron; muscle